Robert F. Kennedy Jr. Addresses Access to Unapproved Peptide Drugs

Health Policy Update

Recently, Robert F. Kennedy Jr., the Health and Human Services Secretary, initiated measures to increase access to certain peptide drugs that are not FDA approved. He introduced a draft policy stating that compounding pharmacies could prepare six specific peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. These peptides have been promoted with wellness claims despite lacking FDA approval.

Compounding Pharmacies Role

Compounding pharmacies are known for preparing personalized medications by mixing ingredients tailored for individual patients. Kennedy’s policy suggests that with appropriate safeguards, these pharmacies could provide a controlled alternative for patients seeking these peptides.

FDA’s Stance and Advisory Panel’s Recommendation

An FDA advisory panel previously voted to recommend the use of these six peptides for compounding. This vote acknowledged patient choice and protection but did not provide FDA approval due to insufficient evidence on the peptides’ safety and efficacy as per FDA scientists.

Policy Provisions and Safety Measures

The policy emphasizes quality and safety, requiring patient-specific prescriptions and traceable ingredients. Pharmacies must conduct quality testing and safety reporting to enhance transparency. Kennedy asserts that this approach offers a regulated alternative to peptides sold by unregulated sources.

Public Comments and Future Plans

The draft policy will be open to public comment until November 13. It will be active until the FDA establishes a rule regarding compounded peptides, though no proposal is currently on the table.

Concerns Raised

Concerns were highlighted in a CBS News report, where an experimental peptide weight-loss drug was found lacking the peptide it claimed to have. Many clinics are promoting peptides like retatrutide even though clinical trials are not complete, and these drugs lack FDA scrutiny.